Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

Allergan PLC tried to put the most positive spin on it, but top-line two-year data from a Phase IIb study of its lead NASH candidate cenicriviroc has analysts wondering what’s the drug’s benefit will be if any. With Allergan revealing Sept. 22 that after two years of treatment, cenicriviroc (CVC) showed no meaningful difference compared to placebo in reducing fibrosis score in NASH patients, Credit Suisse went as far as removing potential revenue for the drug from its modeling.

The Dublin-domiciled specialty pharma claimed that the two-year data from CENTAUR testing CVC, a dual CCR2/CCR5 inhibitor, “supports continued development” of the drug in a Phase III trial initiated this...